These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 9758554

  • 1. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract] [Full Text] [Related]

  • 2. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct 02; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract] [Full Text] [Related]

  • 3. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Schölzel-Dorenbos CJ.
    Ned Tijdschr Geneeskd; 2002 Mar 09; 146(10):494. PubMed ID: 11913117
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
    Erkinjuntti T, Skoog I, Lane R, Andrews C.
    Int J Clin Pract; 2003 Nov 09; 57(9):756-60. PubMed ID: 14686563
    [Abstract] [Full Text] [Related]

  • 7. [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
    Gasser US, Gasser T.
    MMW Fortschr Med; 2001 Dec 13; 143(51-52):40-1. PubMed ID: 11824165
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG.
    Eur Neurol; 2002 Dec 13; 47(1):64-70. PubMed ID: 11803198
    [Abstract] [Full Text] [Related]

  • 10. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR.
    Int J Clin Pract Suppl; 2002 Jun 13; (127):37-44. PubMed ID: 12139366
    [Abstract] [Full Text] [Related]

  • 11. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW, Lloyd JR, Hjelmstad GO, Strausbaugh HJ.
    Pharmacoeconomics; 2000 Dec 13; 18(6):609-12. PubMed ID: 11227398
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
    McMillan H.
    Int J Geriatr Psychiatry; 1999 Dec 13; 14(12):1078-9. PubMed ID: 10607978
    [No Abstract] [Full Text] [Related]

  • 15. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Richard E, Walstra GJ, van Campen J, Vissers E, van Gool WA.
    Ned Tijdschr Geneeskd; 2002 Jan 05; 146(1):24-7. PubMed ID: 11802333
    [Abstract] [Full Text] [Related]

  • 16. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
    Moerkens RM, Dhondt AD.
    Ned Tijdschr Geneeskd; 2003 Apr 05; 147(14):679; author reply 679. PubMed ID: 12712654
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
    Liang YQ, Tang XC.
    Neurosci Lett; 2004 May 06; 361(1-3):56-9. PubMed ID: 15135892
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
    Selai CE, Trimble MR, Rossor MN, Harvey RJ.
    BMJ; 1999 Sep 04; 319(7210):641-2. PubMed ID: 10523095
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.